Table 4.
Multivariate analysis of Cox proportional hazards model of 5-year OS and PFS for the patients of the IC + CCRT group (n = 134)
| Prognostic factors | OS | PFS | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95 % CI | p value | Hazard ratio | 95 % CI | p value | |
| LMR: high versus low | 0.362 | 0.181–0.523 | 0.010 | 0.329 | 0.325–0.693 | 0.018 |
| HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA | 0.203 | 0.025–0. 425 | 0.001 | 0.317 | 0.104–0.672 | 0.028 |
| Age: ≤46 versus >46 | 0.532 | 0.121–0.727 | 0.063 | 1.021 | 0.876–3.672 | 0.153 |
| FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA | 0.186 | 0.087–0.439 | 0.035 | 0.238 | 0.0137–0.639 | 0.033 |
| pathological type: SCC versus ADC versus ASC versus UDC | 0.416 | 0.087–0.539 | 0.010 | 0.286 | 0.187–0.441 | 0.011 |
| Lymph node status classification: positive lymph node versus negative lymph node | 1.475 | 0.987–3.439 | 0.043 | 2.753 | 1.587–4.339 | 0.045 |
| ALC: high versus low | 0.460 | 0.108–0.732 | 0.030 | 0.421 | 0.265–0.828 | 0.001 |
| AMC: high versus low | 1.814 | 1.049–3.738 | 0.131 | 0.682 | 0.212–1.225 | 0.135 |
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count